CLINICAL AND PARA-CLINICAL FEATURES OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Main Article Content
Abstract
Objective: Describe clinical and para-clinical characteristics of primary CNS lymphoma; Research subjects and methods: Prospective Cross-sectional descriptive study conducted on 35 PCNSL patients treated at the Hematopoietic System Department of Hospital K from May 2019 to May 2022. Results: The average age of patients was 56.66 years; Men accounted for 54.3%; Typical clinical symptoms of primary CNS lymphoma are headache 77.1%, and hemiplegia 20%. Pathology results were diffuse large B-cell non-Hodgkin lymphoma 94.3%; activated B-cell type accounts for 74.3%; Typical Immune markers were CD20: 100%; Bcl6: 62.9%; MUM1: 62.9%; Bcl2: 11.4%, Ki67 average 78%. All patients had tumors located in the brain parenchyma. The proportion of patients with multiple brain tumors accounts for 74.3%. The highest incidence of tumors in the frontal lobe was 40%; The incidence of tumors in the occipital lobe was 25.7%; The incidence of tumors in the temporal lobe was 22.9%; The incidence of tumors in the parietal lobe was 20.0%; The incidence of tumors in the cerebellum was 11.4%. Conclusion: Primary CNS lymphoma is common in people over the age of 50, male gender, typical symptoms are headaches, may be accompanied by hemiplegia, the disease is usually large B-cell non-Hodgkin lymphoma, ABC type and often has lesions in the frontal and occipital lobes.
Article Details
Keywords
PCNSL (primary central neuvous system lymphoma)
References
2. Louis BN et al. Primary CNS lymphoma. NCCN guidelines, version 32020. 2020:12-150.
3. Antonio Omuro. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015:1403-1410.
4. Nguyễn Trường Sơn. Bước đầu đánh giá hiệu quả phác đồ Methotrexate liều cao trong điều trị Lymphoma não nguyên phát tại Bệnh viện Chợ Rẫy năm 2008-2010. Y Học TP Hồ Chí Minh. 2011;15(2):14-19.
5. James L. Rubenstein. Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202). Journal of clinical oncology. 2013:3061-3073.
6. Barbara Jezersek Novakovic. Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 – a single centre report. Radiol Oncol. 2012;46(4):346-353.
7. Kuker W NT, Korfel A, et al.,. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005:169-177.